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Background: The effects of pre-transplantation medication for secondary hyperparathyroidism on post-transplantation
parathyroid hormone (PTH) and calcium levels have not yet been conclusively determined. Therefore, this study sought
to determine the level of off-label use of cinacalcet and to determine predictors of its administration during the
long-term follow-up of a cohort of individuals who received deceased-donor renal transplants. Furthermore,
safety considerations concerning the off-label use of cinacalcet are addressed.
Methods: This was a case-control study of 355 stable renal transplant recipients. The patient cohort was divided
into two groups. Transplant group A comprised patients who did not receive cinacalcet treatment, and transplant
group B comprised patients who received cinacalcet treatment during follow-up after renal transplantation. The
characteristics of the patients were evaluated to determine predictors of cinacalcet use after successful renal
transplantation.
Results: Compared with the control individuals (n = 300), the cinacalcet-treated individuals (n = 55) had significantly
higher PTH levels at 4 weeks post-transplantation (20.3 ± 1.6 versus 40.7 ± 4.0 pmol/L, p = 0.0000) when they were drug
naive. At 3.2 years post-transplantation, cinacalcet-treated patients showed higher PTH (26.2 ± 2.3 versus 18.4 ± 2.3
pmol/L, p = 0.0000), higher calcium (2.42 ± 0.03 versus 2.33 ± 0.01 mmol/L, p = 0.0045) and lower phosphate (0.95 ± 0.04
versus 1.06 ± 0.17 mmol/L, p = 0.0021) levels. Individuals in the verum group were more likely to receive cinacalcet
therapy (45.5% versus 14.3%, p = 0.0000), and they had higher pill burdens for the treatment of hyperparathyroidism
(1.40 ± 0.08 versus 0.72 ± 0.03 pills per patient, p = 0.0000) whilst they were on the waiting list for transplantation.
Regression analysis confirmed the associations between hypercalcaemic hyperparathyroidism and PTH levels at 4 weeks
post-transplantation (p = 0.0001), cinacalcet use (p = 0.0000) and the preoperative total pill burden (p = 0.0000). Renal
function was the same in both groups.
Conclusions: Parathyroid gland dysfunction pre-transplantation translates into clinically relevant hyperparathyroidism
post-transplantation, despite patients being administered more intensive treatment whilst on dialysis. PTH levels at
4 weeks post-transplantation might serve as a marker for the occurrence of hypercalcaemic hyperparathyroidism during
follow-up.
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Although the spontaneous resolution of renal hyperpara-
thyroidism after kidney transplantation has been described,
persistent hyperparathyroidism with hypercalcaemia is fre-
quently encountered during follow-up in renal transplant
patients [1,2]. Hypercalcaemia has been associated with
vascular calcifications, nephrolithiasis, tubular microcalcifi-
cations and the deterioration of renal transplant function
[3]. Parathyroidectomy is an invasive therapy with inherent
potential complications, including acute and chronic hypo-
calcaemia, persistent hypoparathyroidism and subsequent
adynamic bone disease. Furthermore, the negative impact
of parathyroidectomy on kidney function in transplant re-
cipients has been demonstrated [4]. Accordingly, an effect-
ive and safe therapeutic alternative is warranted for renal
transplant patients who have persistent hypercalcaemic
hyperparathyroidism. Cinacalcet was first approved for use
in end-stage renal disease (ESRD) patients on chronic
renal replacement therapy in March 2004 in USA and in
October 2004 in Germany. It is the only available allosteric
activator of the calcium-sensing receptors in the human
parathyroid gland [5]. Several studies have reported on its
beneficial use in patients suffering from primary hyper-
parathyroidism [6]. The effects of cinacalcet administered
after kidney transplantation have been demonstrated in
small retrospective [7-9] and prospective [10-12] clinical
studies. However, a major concern is the potential for
marked hypercalciuria with nephrocalcinosis following
cinacalcet administration once kidney function is restored
[13,14]. The use of cinacalcet in renal transplant patients
remains off-label because of safety concerns with regard to
kidney function.
The aim of this study was to evaluate the level of the
off-label use of cinacalcet and to determine predictors of
its administration during the long-term follow-up of a
cohort of individuals who received deceased-donor renal
transplants. Furthermore, safety considerations concern-
ing the off-label use of cinacalcet are addressed.
Materials and methods
Study approval
The study was approved by the local ethics committee.
Data were coded in a manner that ensured subjects
could not be identified either directly or through linked
identifiers. The clinical and research activities reported
are consistent with the “Principles of the Declaration of
Helsinki” [15].
Study population
We analysed 355 patients who received deceased-donor
renal transplants between January 2004 and December
2010. The patients comprised 209 (58.9%) men and 146
(41.1%) women. The average age of the patients at the
time of renal transplantation was 53.9 years, and they hadbeen on chronic renal replacement therapy for approxi-
mately 6.4 years. The mean follow-up period for the co-
hort was 3.2 years. The causes of renal failure included
chronic glomerulonephritis (34.1%), autosomal-dominant
polycystic kidney disease (14.6%), interstitial nephritis and
chronic reflux (8.2%), systemic lupus erythematosus
(1.1%), diabetes (3.9%), other causes (19.2%) and un-
known causes (18.9%). Of the 355 transplant recipients,
298 (83.9%) patients had received their first, 44 (12.4%)
patients had received their second, 12 (3.4%) patients
had received their third and one (0.3%) patient had re-
ceived her fourth renal allograft. At the time of their last
visits to our out-patient clinic, 254 (71.5%) patients were
on tacrolimus-, 86 (42.2%) patients were on cyclosporine-,
eight (2.3%) patients were on everolimus- and seven
(2.0%) patients were on sirolimus-based immunosuppres-
sive regimens. The patient cohort was divided into two
groups. Transplant group A comprised patients who did
not receive cinacalcet treatment, and transplant group B
comprised patients who received cinacalcet treatment
during follow-up after renal transplantation.
Standard values for routine blood chemistry tests
The standard values used for routine blood chemistry tests
were as follows: creatinine < 0.9 mg/dL; calcium 2.10–
2.42 mmol/L, phosphate (0.89–1.45 mmol/L), alkaline
phosphatase (35–104 U/L) and parathyroid hormone
(PTH) (1.6–6.9 pmol/L).
Data acquisition
All data were extracted from clinical charts or electronic
databases, including the hospital's laboratory database
and Eurotransplant's electronic resource.
Statistical analysis
The main “outcome variable” was a “cinacalcet prescrip-
tion” at the time of the patient's final visit to our out-
patient clinic, and we analysed its relationship with several
covariates. The continuous variables included: the dialysis
vintage (years), age at the time of renal transplantation
(years), creatinine concentration (mg/dL), calcium con-
centration (mmol/L), phosphate concentration (mmol/
L), alkaline phosphatase concentration (U/L), parathy-
roid hormone (PTH) level 4 weeks post-transplantation
(pmol/L), PTH level at the end of the follow-up period
(pmol/L), estimated glomerular filtration rate (eGFR),
determined using the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) formula, and the follow-
up time (years). The categorical variables included sex,
parathyroidectomy, cinacalcet treatment, vitamin D treat-
ment, the total pill burden for the treatment of renal
hyperparathyroidism whilst on the waiting list and the im-
munosuppressive regimen administered.
Tillmann et al. Transplantation Research  (2014) 3:21 Page 3 of 6The variables “parathyroidectomy” and “vitamin D treat-
ment whilst on the waiting list” were defined as total and
subtotal operative procedures and medication with plain
or active vitamin D derivatives immediately before trans-
plantation, respectively. Descriptive statistics including the
means, standard errors and proportions are presented for
each variable of interest. The Kolmogorov-Smirnov test
was used to determine whether the data were normally
distributed. The Mann-Whitney U and the chi-square
tests were used to analyse inter-group differences. The
Bonferroni method was applied to adjust for the effects of
multiple testing, and a p value of < 0.0071 was considered
statistically significant.
Univariate logistic regression analysis was performed
for the continuous and categorical variables of interest
to evaluate the predictors of and to determine the risk
ratios (RRs) for the outcome parameter, that is, cinacal-
cet use post-transplantation. For each significant vari-
able, the RR, 95% confidence intervals and p values were
reported. The statistical analyses were performed using
the Statistical Package for the Social Sciences 14.0 for
Windows (SPSS Inc., Chicago, IL, USA).Table 1 Overview statistical results of continuous and catego
transplant group B (cinacalcet) on follow-up
Transplant group A control
(n = 300, 84.5%)
Variable Mean + SE 95% CI Rang
Dialysis vintage (years) 6.33 ± 0.19 5.95–6.70 23.62
Age at time of RTx (years) 53.67 ± 0.73 52.2–55.1 54.9
Creatinine (mg/dL) 1.81 ± 0.04 1.73–1.90 4.80
Calcium (mmol/L) 2.33 ± 0.01 2.30–2.35 1.42
Phosphate (mmol/L) 1.06 ± 0.17 1.02–1.09 1.83
AP (U/L) 83 ± 3 78–89 545
PTH 4 weeks post-transplant (pmol/L) 20.3 ± 1.6 17.2–23.5 332
PTH on follow-up (pmol/L) 18.4 ± 2.3 13.8–23.0 474.9
eGFR (CKD-EPI formula) 44.4 ± 1.2 42.0–46.7 121.6
Follow-up after RTx (years) 3.26 ± 0.12 3.03–3.48 8.08
Gender (%) ♂ 60.3 ♀ 39.7 -
Parathyroidectomyb (%) Yes 27.3 No 72.7 -
Cinacalcet use on waiting list (%) Yes 14.3 No 85.7 -
Vitamin D use on waiting listb (%) Yes 60.0 No 40.0 -
HPT pill burden on waiting listb 0.72 ± 0.03 0.65–0.79 2
The Mann-Whitney U test and Fisher's exact test were used to compare for inter-
was considered significant). To test for predictors of cinacalcet use after renal tran
significant variables were calculated. Risk ratios and their respective 95% CI were
phosphate for an increase of 1.0 mmol/L and PTH 4 weeks post-transplant for an incre
(not shown in the table) were: 0.0039 for calcium, 0.0124 for phosphate, 0.0001 for PTH
list, respectively.
SE standard error, RTx renal transplantation, HPT hyperparathyroidism.
aThe variable “PTH on follow-up” was not significant on logistic regression (p value
bThe variables “parathyroidectomy”, “vitamin D use on waiting list” and HPT “pill bu
and active vitamin D derivatives and pill counts of cinacalcet and vitamin D derivatResults
The characteristics of the patients within the two study
groups are presented in Table 1. Approximately 15.5% of
our patient cohort was prescribed cinacalcet as an off-label
medication during the follow-up period after successful
renal transplantation. At 3.2 years post-transplantation,
patients who were treated with cinacalcet had higher
mean calcium levels (2.42 ± 0.03 versus 2.33 ± 0.01 mmol/
L, p = 0.0045), lower phosphate levels (0.95 ± 0.04 versus
1.06 ± 0.17 mmol/L, p = 0.0021), higher PTH levels
4 weeks after transplantation (40.7 ± 4.0 versus 20.3 ±
1.6 pmol/L, p = 0.0000) when they were drug naive,
higher PTH levels at the end of the follow-up period
(26.2 ± 2.3 versus 18.4 ± 2.3 pmol/L, p = 0.0000) and
higher pill burdens for the treatment of hyperparathyr-
oidism whilst they were on the waiting list (1.40 ± 0.08
versus 0.72 ± 0.03 pills, p = 0.0000), and they were more
likely to have been prescribed cinacalcet whilst they
were wait listed (45.5% versus 14.3%, p = 0.0000), com-
pared with the patients who had not received cinacal-
cet. Renal transplant function, which was determined
using the CKD-EPI formula, was similar for the tworical variables of transplant group A (control) and
Transplant group B cinacalcet
(n = 55, 15.5%)
e Mean + SE 95% CI Range p value RR 95% CI
6.88 ± 0.32 6.24–7.53 11.06 0.0417 - -
55.1 ± 1.3 52.6–57.6 33.7 0.5915 - -
1.64 ± 0.09 1.45–1.83 3.40 0.0589 - -
2.42 ± 0.03 2.37–2.48 0.97 0.0045 1.2 1.1–1.4
0.95 ± 0.04 0.87–1.03 2.02 0.0021 0.2 0.1–0.7
100 ± 6 78–101 262 0.0608 - -
40.7 ± 4.0 32.8–48.7 135 0.0000 1.5 1.2–1.8
26.2 ± 2.3 21.6–30.8 72.4 0.0000a - -
47.4 ± 2.6 42.1–52.6 86.3 0.2435 - -
3.50 ± 0.26 2.98–4.03 7.57 0.3641 - -
♂ 50.9 ♀ 49.1 - 0.2330 - -
Yes 16.4 No 83.6 - 0.0948 - -
Yes 45.5 No 54.5 - 0.0000 5.0 2.7–9.3
Yes 65.5 No 35.5 - 0.5481 - -
1.40 ± 0.08 1.24–1.56 2 0.0000 5.2 3.1–8.7
group differences of continuous and categorical variables (a p value < 0.0071
splantation, univariate logistic regression was applied and risk ratios (RRs) of
calculated for increments as follows: calcium for an increase of 0.1 mmol/L,
ase of 20 pmol/L. On univariate logistic regression, p values of significant variables
at time of RTx, 0.0000 for pill burden and 0.0000 for cinacalcet use on waiting
0.2003).
rden on waiting list” encompass total and subtotal operative procedures, plain
ives, respectively.
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1.73 m2, p = 0.2435).
Univariate regression analysis to determine the predic-
tors of cinacalcet use post-transplantation showed sig-
nificant associations with calcium levels (RR = 1.2 for an
increase of 0.1 mmol/L, p = 0.0039), phosphate levels
(RR = 0.2 for an increase of 1.0 mmol/L, p = 0.0124), the
PTH level at the time of renal transplantation (RR = 1.5
per increase of 20 pmol/L, p = 0.0000), an increased pill
burden for the treatment of hyperparathyroidism whilst
on the waiting list (RR = 5.2 per pill, p = 0.0000) and
“cinacalcet use whilst on the waiting list” (RR = 5.0, p =
0.0000). The immunosuppressive therapy regimens did
not differ significantly between the study groups (p =
0.7863) (Table 2).
Discussion
Approximately 15.5% of our stable renal transplant re-
cipients had been prescribed cinacalcet during the
follow-up period after successful renal transplantations.
Cinacalcet-treated patients were administered more
rigorous medical regimens for the treatment of renal
hyperparathyroidism pre-transplantation, which could
be considered a marker for the acquisition of more se-
vere forms of renal hyperparathyroidism whilst patients
are on chronic renal replacement therapy. Furthermore,
an association between cinacalcet use after transplant-
ation and a reduction in transplant function could not
be determined. Hypercalcaemia as a consequence of
persistent hyperparathyroidism is frequently encoun-
tered in renal transplant patients during their routine
follow-up visits, and it can lead to increased risks of
osteoporosis, fractures, nephrocalcinosis, pancreatitis,
vascular calcifications, hypophosphataemia and a re-
duction in graft function. The limited utility of vitamin
D sterols in the treatment of post-transplantation
hypercalcaemic hyperparathyroidism means that cinacal-
cet represents the only pharmacological approach to the
treatment of these patients. In small, non-randomised
clinical studies, cinacalcet effectively reduced calcium and
PTH levels and it helped to normalise phosphate levels
[16]. Cinacalcet allosterically modifies the calcium-sensing
receptors on the thick ascending limb of Henle, thereby
increasing renal calcium excretion [17]. Several reports
have documented hypercalciuria after the introduction ofTable 2 Overview of immunosuppressive regimens in
absolute numbers and percentages; mTORs = sirolimus
and everolimus, chi-square p = 0.7863
Cyclosporin Tacrolimus mTORs Numbers
Transplant group A
(control)
72 (24.0) 216 (72.0) 12 (4.0) n = 300
Transplant group B
(cinacalcet)
14 (25.5) 38 (69.0) 3 (5.5) n = 55cinacalcet treatment to renal transplant patients [10,18],
and some reports have linked hypercalciuria to nephrocal-
cinosis and a decline in graft function [13,19]. However,
other studies have determined that cinacalcet has no effect
on renal calcium excretion [11,12]. These disparate find-
ings might be explained by the time-dependent effect of
cinacalcet in relation to renal calcium handling, because it
increases calcium excretion within the first 8 h of its ad-
ministration and has no further effects thereafter [20].
Other investigations have also reported on safety issues
with respect to the potentially negative impact of cinacal-
cet therapy on renal graft function [14,21,22], but the de-
cline in graft function is relatively small or even reversible
after the cessation of cinacalcet medication, which indi-
cates a hemodynamic effect associated with the drug [23].
In contrast to these findings, other studies could not de-
tect a negative effect of cinacalcet on graft function
[24-26]. With respect to graft function, our data are more
consistent with the latter reports. After an average follow-
up duration of 3.2 years post-transplantation, patients re-
ceiving cinacalcet therapy showed an eGFR that was
3.0 mL/min/1.73 m2 greater than their untreated counter-
parts. Nevertheless, despite cinacalcet treatment, PTH
levels remained significantly higher than those in the con-
trol group, which partially explains the differences in the
calcium and phosphate levels between the study groups.
At our institution, medication for hyperparathyroidism
is usually paused on the day of transplantation and PTH
levels are regularly measured to observe their natural
courses. Jadoul and co-workers found that stopping
cinacalcet treatment on the day of transplantation had
no effect on the courses of the PTH levels during 12-
month follow-up periods in 28 patients [27]. In contrast,
it has been reported that PTH levels are prone to re-
bounds short after the cessation of medication in pa-
tients who received cinacalcet after transplantation
[28,29]. In our study, PTH levels differed significantly
between the groups as early as 4 weeks after transplant-
ation, which concurs with the latter investigations. Fur-
thermore, we were able to demonstrate a tendency
towards reduced parathyroidectomy rates in our study
population, as demonstrated in patients with ESRD on
dialysis [30]. The dialysis vintage was similar in the two
study groups, with a tendency towards longer ESRD
treatment periods in the cinacalcet group. Recently, the
investigators associated with the Evaluation of Cinacalcet
Hydrochloride (HCl) Therapy to Lower Cardiovascular
Events study, which was a placebo-controlled prospective
study of over 3,800 ESRD patients on haemodialysis in an
unadjusted intention-to-treat analysis, reported that cina-
calcet had no effect on cardiovascular endpoints [31].
In contrast to these data, a report from a large cohort
study of over 100,000 ESRD patients on haemodialysis
suggests that improvements in the control of phosphate
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survival [32]. However, these results might not be
transferrable to a transplant setting given the differ-
ences in the characteristics between ESRD patients on
haemodialysis and transplant recipients during follow-
up. As a consequence of the retrospective design of our
study, we were unable to address the safety issues that
are related to potential drug interactions between cina-
calcet and standard immunosuppressive therapeutics,
including calcineurin and mammalian target of rapamy-
cin inhibitors. Since we could not determine any differ-
ences between the two study groups with respect to the
standard immunosuppressive drug regimens, we can
infer that cinacalcet does not have negative impacts on
the standard immunosuppressive drug regimens. Fur-
thermore, Evenepoel and co-workers did not report any
negative drug-to-drug interactions in a prospective
multi-centre study [33]. Analysis of the data from the
pre-transplantation period and the follow-up data, shows
that poorly controlled hyperparathyroidism as a conse-
quence of gland hyperplasia in haemodialysis patients be-
fore transplantation, is not necessarily resolved by renal
transplantation, resulting in poorly controlled hyperpara-
thyroidism for several years after transplantation; hence,
our data indicate that parathyroid gland hyperplasia with
concomitant hyperparathyroidism is transferred and that
it lingers into the post-transplantation era in kidney graft
recipients.
Furthermore, hypercalcaemic hyperparathyroidism oc-
curs in a key subset of long-term kidney transplant re-
cipients. More research into optimal PTH ranges in
transplant candidates who are on waiting lists is neces-
sary to enable the transplant community to achieve bet-
ter control of PTH levels post-transplantation. Although
prescribing cinacalcet to transplant patients seems to be
safe with regard to transplant function, studies that in-
vestigate its use with robust endpoints are clearly war-
ranted to shed more light on the long-term usefulness of
cinacalcet after renal transplantation.Limitations and strengths
There are several limitations to this study. Our study re-
sults clearly require corroboration from investigations
with larger numbers of patients. Given the retrospective
nature of our analysis, we could not account for changes
in medications between the two time points. Finally, our
data were derived from a single centre and from trans-
plant recipients whose genetic backgrounds were from
Caucasian ancestries. Accordingly, these results might
not be applicable to other transplant centres or to patients
with different genetic backgrounds. The key strengths
of our study included the long follow-up period after
renal transplantation, the presence of a control groupand the availability of a combination of pre- and post-
transplantation data.
Conclusion
PTH levels at as early as 4 weeks post-transplantation are
associated with the evolution of hypercalcaemic hyper-
parathyroidism during long-term follow-up assessments
after kidney transplantation. Despite more intensive treat-
ment of renal hyperparathyroidism with cinacalcet and
vitamin D derivatives whilst patients are on dialysis, the
development of more severe forms of post-transplantation
hyperparathyroidism that subsequently affect calcium and
phosphate levels continues to occur in a substantial
number of patients. The off-label use of cinacalcet is
not associated with a decline in transplant function.
Further research into the impacts of treatment algo-
rithms for renal hyperparathyroidism associated with
wait-listed ESRD programmes on outcome parameters
post-transplantation is warranted.
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